173843-49-7

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[(4-methyl-2-nitrophenyl)amino]-, ethyl ester
• CAS NO: 173843-49-7
• Molecular Formula: C15H21N3O4
• Molecular Weight: 307.349
• Mol File: 173843-49-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[(4-methyl-2-nitrophenyl)amino]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[(4-methyl-2-nitrophenyl)amino]-, ethyl ester(173843-49-7)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[(4-methyl-2-nitrophenyl)amino]-, ethyl ester(173843-49-7)

Safety Data

• Hazardous Substances Data: 173843-49-7(Hazardous Substances Data)

Usage

Uses

Antihistamine and sedative medication This property indicates the primary functions of the compound, which are to reduce allergy symptoms and promote relaxation or sedation.

Mechanism of action

Blocks histamine receptors in the brain This specific content explains how the compound works to alleviate allergy symptoms and promote sedation by interacting with histamine receptors in the brain.

Precautions

Can cause drowsiness and impair cognitive and motor function This is an important consideration when using the compound, as it may have side effects that could impact a person's ability to think, reason, or perform physical tasks.

Upstream product

• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 446-11-7 4-fluoro-3-nitrotoluene 
• 89-60-1 1-chloro-4-methyl-2-nitro-benzene 

Downstream Products

• 107618-24-6 ethyl 4-(4-methyl-2-aminoanilino)-1-piperidinecarboxylate 

Relevant articles and documents

Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: Optimization of the 4-substituted piperidine

In our continuing effort to identify CGRP receptor antagonists for the acute treatment of migraine, we have undertaken a study to evaluate alternative 4-substituted piperidines to the lead dihydroquinazolinone 1. In this regard, we have identified the piperidinyl-azabenzimidazolone and phenylimidazolinone structures which, when incorporated into the benzodiazepine core, afford potent CGRP receptor antagonists (e.g., 18 and 29). These studies produced a potent analog (18) which overcomes the instability issues associated with the lead structure 1. A general pharmacophore for the 4-substituted piperidine component of these CGRP receptor antagonists is also presented.

Alpha IC adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1C adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hypertrophy. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha1C receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Synthesis and neuroleptic activity of a series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzimidazolone derivatives

-